Pfizer’s newer products grow 32% as patent expirations approach
Padcev, Nurtec and Lorbrena supported growth in newer and acquired products, while other launches add further potential drivers. Metsera added obesity candidates, including berobenatide, which Pfizer is targeting for potential approval beginning in 2028. The company expects its newer products and pipeline to support a return to growth from 2029, but gains have not yet produced strong overall revenue growth.
Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
Pfizer agreed to pay Starna Therapeutics $330 million upfront, with up to $2.3 billion in milestone payments and royalties, for rights outside Greater China to three preclinical in vivo RNA therapy programs targeting autoimmune diseases. Pfizer also gained rights to use Starna’s technology in inflammation, immunology and oncology, plus options to license other projects and expand its territory. The deal gives Pfizer a new avenue into in vivo cell therapy, an emerging field that could simplify CAR-T treatment and potentially extend it beyond cancer. The programs are early-stage, and safety concerns have led other companies to pause autoimmune CAR-T trials. The agreement is at least Pfizer’s fifth major alliance with a Chinese company since early 2025.
Pfizer CEO says Chinese drugmakers may be its main competitors by 2030
Bourla said Pfizer must sharply cut costs and accelerate drug development, with AI a key potential lever. China aims to develop 25% of the world’s first-in-class drugs by 2030. Rising U.S.-China investment and collaboration restrictions add uncertainty to the competitive landscape.
Pfizer generates $11.8 billion in trailing free cash flow
Pfizer’s free-cash-flow yield may reflect market concern about growth: revenue rose just 1.3%, and U.S. exclusivity losses for Ibrance and Xtandi and international Eliquis losses are expected to weigh on results from 2027. New and acquired products are growing, cost savings are planned, and Pfizer raised its 2026 revenue guidance. Investors will watch 2027 guidance and subsequent cash flow and debt figures.
Pfizer CEO expects high-single-digit growth after patent losses
Bourla cited recent launches that grew 32% last quarter and generate $15 billion–$16 billion in annualized revenue. Pfizer is advancing a monthly obesity treatment, while efficacy and tolerability remain to be confirmed. Pipeline priorities include cancer and immunology programs. The company expects $7.2 billion in net savings by year-end and has announced an additional $1.5 billion in savings.
Pfizer completed its acquisition of Metsera, adding long-acting injectable obesity drug candidates to its portfolio and strengthening its effort to build revenue beyond COVID products. The move supports plans for more than 20 obesity-related trials in 2026, while increasing Pfizer’s exposure to pipeline, launch and pricing risks. The company’s detailed 2027 guidance is expected in December 2026.
Arbutus and Genevant expand patent lawsuits against Pfizer
Arbutus and Genevant expanded patent infringement lawsuits against Pfizer and BioNTech in Japan and Canada, alleging their COVID-19 vaccines use patented lipid nanoparticle technology. Potential licensing costs and liabilities could weigh on vaccine economics. Arbutus also reported third-quarter results, completed a shareholder tender offer and said the FDA lifted a clinical hold on AB-101.
Pfizer shares fall 5.9% after third-quarter results
Growth in newer and acquired products, oncology medicines and cost savings supports a longer-term recovery, while declining COVID-19 sales and patent expirations pose headwinds. Obesity drug berobenatide is advancing but trails leading competitors. Pfizer expects growth to resume from 2029 and offers an approximately 6% dividend yield; Zacks rates the stock Hold, citing its low valuation and growth risks.
Blackstone commits up to $1.5 billion to Pfizer’s obesity drug development
Blackstone Life Sciences will fund development costs for Pfizer’s investigational monthly GLP-1 drug berobenatide through 2028. Blackstone may receive milestone payments tied to U.S. approval and commercial sales, but gains no ownership or control. The funding supports a program of up to 10 Phase 3 trials and reduces Pfizer’s near-term development-cost exposure; the drug’s efficacy, tolerability and commercial prospects remain uncertain.
Pfizer reports positive Phase 3 results for ELREXFIO
Pfizer reported positive Phase 3 MagnetisMM-32 results for ELREXFIO in relapsed or refractory multiple myeloma after anti-CD38 therapy and lenalidomide, showing a statistically significant progression-free survival benefit. Overall-survival data and regulatory decisions remain ahead. Pfizer also partnered with Edison Scientific to use its AI platform across research and development.
Pfizer named Cecile Guegan permanent CFO, making her the company’s first woman in the role. She had served as interim CFO since Dave Denton left for Nike. The appointment comes as Pfizer raises its 2026 revenue guidance to $64 billion after stronger sales of Eliquis and Padcev. Guegan has emphasized financial discipline as the company faces patent losses and seeks growth from its pipeline.
Pfizer reaches a 52-week high as newer products grow
Pfizer’s latest quarter showed flat revenue year over year, but recently launched and acquired products grew 32%. The company says this growth and its drug pipeline may help offset upcoming patent expirations. The article notes Pfizer’s valuation and dividend yield, while presenting the stock as potentially attractive to long-term investors and noting it was not among Motley Fool Stock Advisor’s top 10 picks.
Pfizer raises 2026 revenue outlook to $62 billion–$64 billion
Pfizer’s third-quarter revenue was nearly flat at $16.6 billion, while newer products grew 32% to $3.8 billion. The company raised its 2026 revenue outlook to $62 billion–$64 billion, a $1.5 billion increase at the midpoint. Patent exclusivity losses are expected to weigh on results in 2027, while cost savings and growth in newer products are intended to help offset them.
Pfizer believes its commercial execution and ability to scale could help it compete in the GLP-1 market with berobenatide. Its plans include weekly dosing followed eventually by a monthly injection. The drug still needs regulatory approval, and its success will depend partly on tolerability and weight-loss results. Pfizer sees room to win share despite entering later than rivals.
Pfizer has 10 late-stage obesity drug trials underway
Pfizer’s acquired candidate reduced weight by 12% in trials despite switching to monthly injections, potentially offering a different dosing schedule from competitors’ weekly injections or daily pills. Pfizer is maintaining its dividend, but the trials remain underway, so an approved product and commercial success are not assured. Investors are weighing the company’s prospects against Eli Lilly and Novo Nordisk.
Pfizer shifts focus from declining COVID-19 products to newer drugs
Pfizer is shifting its focus from declining COVID-19 products to newer launched and acquired drugs, which generated $3.8 billion in third-quarter 2026 sales, up 32% operationally. These products represent nearly a quarter of revenue, while total quarterly sales fell 0.4% year over year. The article also cited expected exclusivity losses for Ibrance and Xtandi in the U.S. and international Eliquis competition.
Pfizer raises 2026 guidance after third-quarter results
Pfizer reported third-quarter 2026 revenue of $16.6 billion, broadly unchanged year over year, and basic EPS of $0.57 versus $0.62. Non-COVID products grew 7% operationally, while launched and acquired drugs rose 32% to $3.8 billion. Adjusted earnings were $0.87 per share, and Pfizer expects 2026 adjusted EPS of $2.95 to $3.05.
United Therapeutics pays Pfizer subsidiary $525 million to eliminate ralinepag royalties
United Therapeutics will pay $525 million upfront to Pfizer subsidiary Arena Pharmaceuticals to eliminate all royalties on ralinepag sales. The deal covers oral and inhaled formulations; milestone obligations for certain future approvals remain. Ralinepag’s oral version is under FDA review for pulmonary arterial hypertension, while an inhaled version is in development.
Pfizer’s 2026 share gain faces valuation and execution questions
Pfizer returned 28.6% from the start of 2026, supported by oncology approvals, obesity data and a China-focused cancer partnership. Q3 revenue and net income fell year over year, while net margin declined to 19.6%. The article said the outlook depends on turning obesity, oncology and inflammation pipeline assets into durable non-COVID revenue amid pricing pressure and patent expirations.
Pfizer was scheduled to report Q3 results Tuesday before market open. Analysts expected revenue to fall 4.8% year over year, with estimates broadly unchanged over the previous month. The article noted that Pfizer had beaten revenue and EPS estimates in the prior quarter but missed full-year EPS guidance.